Routine angioplasty after fibrinolysis: how early should "early" be? by Verheugt, F.W.A.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/81650
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
n engl j med 360;26 nejm.org june 25, 2009 2779
edi tor i a l s
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Routine Angioplasty after Fibrinolysis — How Early  
Should “Early” Be?
Freek W.A. Verheugt, M.D.
Reperfusion therapy has represented a great leap 
forward in the management of myocardial infarc-
tion with ST-segment elevation. Its goal is early 
and complete recanalization of the infarct-related 
artery to salvage myocardium and improve both 
early and late clinical outcomes. Complete reper-
fusion can be achieved with either fibrinolysis or 
primary percutaneous coronary intervention (PCI), 
but with primary PCI the success rate is higher 
than 90%, whereas current fibrinolytic therapy 
leads to full reperfusion in only 50 to 55% of re-
cipients. Primary PCI, therefore, looks like the 
most appropriate reperfusion tool, but there are 
substantial logistic restrictions associated with 
it. The door-to-balloon time with primary PCI is 
typically longer than the time within which in-
hospital fibrinolytic therapy can be initiated, and 
primary PCI requires a network of dedicated am-
bulances and emergency departments to shorten 
the door-to-balloon time as much as possible.1,2 
Primary PCI is an especially attractive strategy in 
the United States, where nearly 80% of the adult 
population lives within 1 hour’s drive of a PCI 
center.3
Investigators have tried to combine the best of 
both therapies by performing PCI immediately 
after fibrinolysis. The concept of fibrinolysis fol-
lowed immediately by PCI (termed facilitated PCI) 
seems attractive: early reperfusion with the use 
of a widely available strategy to salvage as much 
myocardium as possible, followed by PCI to en-
sure both reperfusion in the case of fibrinolytic 
failure and prevention of recurrent thrombosis 
that may result in reocclusion and reinfarction. 
Studies of PCI performed immediately after fi-
brinolysis were initiated in the late 1980s, but a 
meta-analysis in 2005 showed that this approach 
was not usually beneficial,4 probably in part be-
cause of the use of outdated fibrinolytic and anti-
platelet regimens and PCI equipment in those 
studies but also because of the increased risk of 
bleeding. The latter concern, especially, made many 
interventional cardiologists reluctant to intervene 
after fibrinolysis, although the results of a trial of 
rescue PCI after failed fibrinolysis suggest that 
this procedure is effective and relatively safe.5 
Since the major problem with the combination of 
fibrinolytic therapy with immediate PCI is thought 
to be the short interval between fibrinolysis and 
PCI, some later studies have investigated the out-
come when a longer interval is used. Besides re-
ducing the risk of bleeding, this approach enables 
the transfer of patients from centers that do not 
have the capability of performing PCI (where ini-
tial fibrinolysis is performed) to a PCI center. 
These studies showed that the approach was suc-
cessful; however, the sample sizes in the studies 
were relatively small.6-9
In this issue of the Journal, Cantor et al. report 
the results of the Trial of Routine Angioplasty and 
Stenting after Fibrinolysis to Enhance Reperfusion 
in Acute Myocardial Infarction (TRANSFER-AMI; 
ClinicalTrials.gov number, NCT00164190), a large 
study on this topic.10 More than 1000 Canadian 
patients with myocardial infarction with ST-seg-
ment elevation who were treated with fibrinolysis 
were randomly assigned to interhospital transfer 
for intended routine early PCI (within 6 hours af-
ter fibrinolysis) or an ischemia-guided strategy, in 
which patients were transferred for angiography 
only in the case of failed fibrinolysis or of recur-
rent ischemia. As in the four smaller trials, the 
rate of recurrent ischemia was significantly re-
duced with early routine PCI as compared with a 
selective invasive approach. Given the sample size 
and the study design, and with little evidence to 
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suggest a risk associated with the transfer itself, 
the trial can be considered definitive, in that it 
confirms earlier randomized studies with a simi-
lar relative risk reduction. Current guidelines for 
the management of myocardial infarction with 
ST-segment elevation in Europe and the United 
States have adopted this strategy with a mod-
erate11 to high12 level of evidence, to which 
TRANSFER-AMI substantially contributes.
The interval from fibrinolysis to PCI and the 
rate of ischemic events in the five available stud-
ies are shown in Figure 1. The time to PCI was 
well within 24 hours after fibrinolysis in each 
study, and there was no difference among the tri-
als in efficacy relative to the time to PCI. The in-
tervals ranged from 2 to 17 hours. The former 
interval should be considered to be the lowest ac-
ceptable one, since PCI immediately after fibrin-
olysis has proved to be ineffective.4 On the other 
hand, an interval of 17 hours seemed to be as 
good as PCI at 2 hours. Waiting longer than 24 
hours can be disadvantageous given the increas-
ing risk of reocclusion of the infarct-related ar-
tery.13 Performing PCI 72 hours or more after the 
event will probably offer no protection against 
reinfarction. In the large Occluded Artery Trial 
(OAT, NCT00004562),14 in which patients were 
randomly assigned to undergo PCI of an occlud-
ed infarct-related artery or not to undergo PCI, 
late opening (72 hours after infarction or longer) 
showed no benefit with respect to reinfarction or 
death. It should be noted that only a quarter of 
the patients in the OAT were given fibrinolytic 
therapy for their index infarction. Thus, it seems 
that the optimal window for early PCI after fibrin-
olysis is somewhere between 2 and 24 hours. This 
observation was recently confirmed in a large 
French registry study of reperfusion therapy for 
myocardial infarction with ST-segment elevation.15
Fibrinolysis is still by far the most frequently 
performed reperfusion strategy for myocardial 
infarction with ST-segment elevation worldwide. 
Should all patients who have received fibrinolytic 
therapy be transferred for early PCI? Given the 
mechanism of early reocclusion and reinfarction 
and the consistent benefit observed in the ran-
domized trials of an early invasive approach, the 
answer should be yes. Transfer must not be on an 
emergency basis, except in the case of patients in 
whom fibrinolysis has failed, and can probably 
wait until the day after fibrinolytic therapy is giv-
en. Such a strategy improves the results of fibrin-
olysis while at the same time allowing a transition 
of care that causes less stress both to the patient 
and to ambulance crews.
Timely primary PCI remains the optimal ther-
apy for myocardial infarction with ST-segment el-
evation; however, owing to the logistic and tem-
poral restraints of primary PCI, fibrinolysis is still 
the only possible initial reperfusion strategy in 
large parts of the world, including large parts of 
the Western world. Fibrinolysis, however, should 
be followed by an early invasive approach; in this 
setting, PCI has a central role.
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Figure 1. Rate of Ischemic Events at the Available Follow-up.
Five major randomized clinical trials have evaluated routine early percuta-
neous coronary intervention (PCI) after fibrinolysis, as compared with fi-
brinolysis alone followed by a selective invasive approach, in patients with 
myocardial infarction with ST-segment elevation. The five trials are the 
Combined Angioplasty and Pharmacological Intervention versus Throm-
bolysis Alone i  Acute Myocardial Infarction (CAPITAL AMI) trial,8 the 
Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction 
(CARESS-in-AMI, NCT00220571),9 the Southwest German Interventional 
Study in Acute Myocardial Infarction (SIAM III),7 the Trial of Routine An-
gioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute 
Myocardial Infarction (TRANSFER-AMI, NCT00164190),10 and Grupo de 
Análisis de la Cardiopatía Isquémica Aguda-1 (GRACIA-1) trial.6
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Cancer Genomes on a Shoestring Budget
Jay Shendure, M.D., Ph.D., and Colin J. Stewart, M.B., Ch.B.
In a remarkably short time, the use of massively 
parallel technologies has greatly reduced the cost 
of DNA sequencing.1 Already, these technologies 
have permitted the whole-genome sequencing of 
several persons2-4 and one tumor 5 for a small frac-
tion of the cost of the sequencing of the first hu-
man genome. However, the cost of whole-genome 
sequencing is still many tens of thousands of 
dollars — too expensive for routine application to 
even modest numbers of samples in either a re-
search or a clinical setting.
In this issue of the Journal, Shah et al.6 de-
scribe the identification of a likely “driver” muta-
tion of the FOXL2 gene in adult-type granulosa-cell 
tumors (GCTs), relatively uncommon neoplasms 
that account for 3 to 5% of all ovarian cancers.7 
The discovery was made by sequencing the tran-
scriptome of tumor specimens, rather than by se-
quencing genomic DNA (gDNA). The transcrip-
tome is defined as the full set of messenger RNA 
(mRNA) present in a population of cells. The usu-
al goal of characterizing a transcriptome is to 
quantify the relative abundance with which indi-
vidual genes are expressed in a given tissue (e.g., 
with microarrays). In contrast, the objective of 
this study was to mine transcribed sequences to 
indirectly identify nonsynonymous mutations in 
the tumor genome — that is, those altering pro-
tein-coding sequences.
To put this in context, more than 98% of the 
human genome comprises sequences with regu-
latory or unknown function, interspersed with 
nearly 200,000 exons that collectively encode 
mRNA (the “exome” contributing 1 to 2% of the 
genome in aggregate); mRNA, in turn, encodes 
proteins. The vast majority of somatic mutations 
that have been identified to date and that clearly 
drive the development of cancer in humans are 
either large-scale structural changes (e.g., rear-
rangements and copy-number changes) or small 
mutations that alter protein-coding sequences. 
Whole-genome sequencing of a tumor (and 
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